Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain, gives an overview of his talk on whether or not there is a need to improve the assessment of response in relapsed myeloma. Dr Paiva talks about how overall response rates have improved in relapsed/refractory myeloma with the development of novel agents and a fraction of patients can achieve complete response (CR). The question is whether the response criteria need to be improved in relapsed myeloma. According to Dr Paiva, the data suggests that patients could benefit by improving response critera after incorporating minimal residual disease (MRD) techniques.
Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.